ReviewJournal of thoracic disease2026
Clinical research advances in thoracic surgery and thoracic oncology in 2025: a panoramic narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The year 2025 brought important refinements in thoracic surgery and thoracic oncology, particularly in risk-adapted screening, biomarker-guided perioperative therapy, minimally invasive surgery, and perioperative recovery. This narrative review summarizes clinically relevant evidence reported in 2025 and discusses how these updates may influence multidisciplinary practice. Methods: We conducted a narrative review of literature and conference reports published or presented between January 1 and December 31, 2025. PubMed, Google Scholar, and the official abstract proceedings/websites of the American Society of Clinical Oncology (ASCO), the World Conference on Lung Cancer (WCLC), and the European Society for Medical Oncology (ESMO) were searched using combinations of disease-, treatment-, and surgery-related keywords. Earlier pivotal trials were cited selectively to provide background context where needed. Key Content and Findings: The National Comprehensive Cancer Network (NCCN) updated lung cancer screening criteria toward broader risk inclusion. In resectable non-small cell lung cancer (NSCLC), 2025 data further refined perioperative strategies for molecularly selected and driver-negative populations, including long-term outcomes from immunotherapy trials and phase III evidence for neoadjuvant targeted therapy. Robot-assisted thoracic surgery (RATS) continued to show advantages in selected complex settings, especially after induction treatment. Progress in mesothelioma, esophageal cancer, perioperative rehabilitation, and digital symptom monitoring also underscored the increasing importance of whole-patient care. However, several emerging tools, including circulating tumor DNA (ctDNA) and artificial intelligence (AI)-assisted models, still require prospective validation, standardization, and broader accessibility before routine implementation. Conclusions: Recent advances in thoracic oncology increasingly support a more precise, multidisciplinary, and patient-centered model of care. The most meaningful progress in 2025 lay not only in new treatments, but also in better integration of molecular stratification, surgical decision-making, and perioperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.